-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EsfL+PoNdvUzcebOcm7bduTTe4A7BoVYJV99xZ/ZFrWBCRd3PZ20aIejRlSA01J1 zdm9B1ThJIEBDF7k+CTi7g== 0001157523-04-006849.txt : 20040728 0001157523-04-006849.hdr.sgml : 20040728 20040726191015 ACCESSION NUMBER: 0001157523-04-006849 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20040723 ITEM INFORMATION: ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20040727 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DIAGNOSTIC PRODUCTS CORP CENTRAL INDEX KEY: 0000702259 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 952802182 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-09957 FILM NUMBER: 04931897 BUSINESS ADDRESS: STREET 1: 5700 W 96TH ST CITY: LOS ANGELES STATE: CA ZIP: 90045 BUSINESS PHONE: 3106458200 8-K 1 a4688611.txt DIAGNOSTIC PRODUCTS CORP. 8-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 --------------------------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 23, 2004 ------------- Diagnostic Products Corporation ------------------------------- (Exact name of Registrant as specified in its charter) California 1-9957 95-2802182 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 5700 West 96th Street, Los Angeles, California 90045 ---------------------------------------------------- (Address of principal executive offices) (Zip Code) (310) 645-8200 -------------- (Registrant's telephone number, including area code) Diagnostic Products Corporation Current Report on Form 8-K ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS. (c) Exhibits. No. 99.1 Press Release issued by Diagnostic Products Corporation, dated July 23, 2004. ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On July 23, 2004, Diagnostic Products Corporation announced its results of operations for the quarter June 30, 2004. A copy of the related press release is being furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference in its entirety. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: July 23, 2004 Diagnostic Products Corporation By: /s/ James L. Brill ----------------------------- James L. Brill, Vice President, Finance EXHIBIT INDEX Exhibit Number - -------------- 99.1 Press Release issued by Diagnostic Products Corporation, dated July 23, 2004. EX-99.1 2 a4688611ex991.txt PRESS RELEASE EXHIBIT 99.1 Diagnostic Products Corporation Announces Record Sales and Earnings LOS ANGELES--(BUSINESS WIRE)--July 23, 2004--Diagnostic Products Corporation (NYSE:DP) today reported record sales of $110.5 million for its second quarter, a 15% increase over the second quarter of 2003. Earnings were $18.6 million, or $.62 per diluted share, an increase of 12% from $16.6 million or $.56 for the second quarter of 2003. The dollar weakened relative to the Euro, but strengthened relative to the Real in the second quarter of 2004. Overall changes in currencies had a 3% positive impact on sales. International sales were $78.4 million and domestic sales were $32.1 million. Sales of IMMULITE products continued to be very strong, growing 18% over the second quarter of 2003. IMMULITE product line sales reached $100.8 million for the quarter, 91% of the total sales of the Company. IMMULITE reagent sales increased 20% this quarter over the second quarter of 2003. Sales of RIA products were $6.1 million, a 12% decline from last year's second quarter. Sales of other products were $3.6 million, down from $3.8 million in the same period last year. The Company shipped a total of 246 IMMULITE Instruments in the second quarter including 185 IMMULITE 2000s and 2500s. The total number of IMMULITEs shipped is now over 9,400. "Our IMMULITE business continues to do very well," said Michael Ziering, President and CEO of DPC. "We were particularly pleased with the number of IMMULITE 2000s and 2500s which were shipped this quarter." Founded in 1971, Diagnostic Products Corporation (DPC) is the global leader dedicated exclusively to immunodiagnostic testing. The Company's product menu includes about 100 immunoassays for medically important substances and nearly 350 specific allergens and allergy panels. DPC also designs and manufactures automated laboratory instrumentation which provides fast, accurate results while reducing labor and reagent costs. DPC sells its products to hospitals, clinics and laboratories domestically and in over 100 international countries. Additional Company information can be found on the Company's web site at www.dpcweb.com. Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially. These factors include the effects of governmental and other actions relating to the FDA's decision that its Application Integrity Policy should be applied to the Company or relating to the Company's Chinese affiliate; the rate of customer demand for the Company's products; Company's ability to successfully market new and existing products; its dependence on certain suppliers; domestic and foreign government regulation; its ability to keep abreast of technological innovations and to translate them into new products; competition; political and economic instability in certain markets including the movements of foreign currencies relative to the dollar; and other risks and uncertainties disclosed from time to time in the Company's SEC reports and filings. Diagnostic Products Corporation and Subsidiaries Consolidated Statements of Income (Unaudited -- In thousands except per share data) Three Months Ended June 30, 2004 2003 SALES: Non-Affiliated Customers $102,749 $88,186 Unconsolidated Affiliates 7,719 7,765 Total Sales 110,468 95,951 COST OF SALES 44,816 39,964 Gross Profit 65,652 55,987 OPERATING EXPENSES: Selling 19,382 15,622 Research and Development 11,025 10,047 General and Administrative 11,058 8,308 Equity in Income of Affiliates (2,700) (1,463) OPERATING EXPENSES -- NET 38,765 32,514 OPERATING INCOME 26,887 23,473 Interest/Other Income (Expense) -- Net (184) 124 INCOME BEFORE INCOME TAXES AND MINORITY INTEREST 26,703 23,597 PROVISION FOR INCOME TAXES 8,011 6,843 MINORITY INTEREST 73 132 NET INCOME $18,619 $16,622 EARNINGS PER SHARE: BASIC $.64 $.58 DILUTED $.62 $.56 WEIGHTED AVERAGE SHARES OUTSTANDING: BASIC 29,059 28,690 DILUTED 29,866 29,659 CONTACT: Diagnostic Products Corporation James L. Brill, 310-645-8200 -----END PRIVACY-ENHANCED MESSAGE-----